Tech Company Financing Transactions
Tioga Pharmaceuticals Funding Round
Thomas, McNerny & Partners and Genesys Capital joined a $10 million Series B capital raise for Tioga Pharmaceuticals. The funding round was announced on 4/12/2012.
Transaction Overview
Company Name
Announced On
4/12/2012
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series B
Investors
Thomas, McNerny & Partners (Lead Investor) (Jason Brown)
Proceeds Purpose
Tioga is currently conducting a Phase 3 trial of its compound, asimadoline, for the treatment of diarrhea-predominant irritable bowel syndrome (D-IBS) under a special protocol assessment with the U.S. Food and Drug Administration (FDA).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4747 Executive Dr. 700
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Not Recorded
Overview
Tioga Pharmaceuticals is engaged in the development of novel therapies for the treatment of gastrointestinal diseases. Tioga is developing asimadoline, a proprietary small molecule, for treating irritable bowel syndrome (IBS) and post operative ileus.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stuart Collinson
Chief Medical Officer
Dawn McGuire
Chief Operating Officer
Sophie Visonneau
Browse more venture capital transactions:
Prev: 4/12/2012: TalkTo venture capital transaction
Next: 4/12/2012: appRenaissance venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs